BamSEC and AlphaSense Join Forces
Learn More

Korsana Biosciences Inc. – Material Contracts

NASDAQ: KRSA    
Share price (9/22/26): $34.98    
Market cap (9/22/26): $23.4 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.21
from 8-K 11 pages September 8, 2026 Matthew Leoni [***] [***] Email: [***] Re: Offer of Employment Dear Matthew
12/34/56
EX-10.20
from 8-K 11 pages September 8, 2026 Mark Vignola [***] [***] Email: [***] Re: Offer of Employment Dear Mark
12/34/56
EX-10.19
from 8-K 11 pages September 8, 2026 Jonathan Violin [***] [***] Email: [***] Re: Offer of Employment Dear Jon
12/34/56
EX-10.10
from 8-K 16 pages Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.9
from 8-K 20 pages Korsana Biosciences, Inc. 2026 Stock Incentive Plan
12/34/56
EX-10.6
from 8-K 10 pages Indemnification Agreement
12/34/56
EX-10.5
from 8-K 22 pages Contingent Value Rights Agreement
12/34/56
EX-10.30
from S-4/A 51 pages License Agreement
12/34/56
EX-10.20
from S-4/A 2 pages First Amendment to the Korsana Biosciences, Inc. 2025 Equity Incentive Plan
12/34/56
EX-10.34
from S-4/A 26 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type of Information That the Registrant Both Customarily and Actually Treats as Private and Confidential. Biologics Master Services Agreement
12/34/56
EX-10.33
from S-4/A 3 pages Amendment No. 1 to the Cell Line License Agreement
12/34/56
EX-10.32
from S-4/A 17 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type of Information That the Registrant Both Customarily and Actually Treats as Private and Confidential. Cell Line License Agreement
12/34/56
EX-10.31
from S-4/A 6 pages 1 Research Program
12/34/56
EX-10.30
from S-4/A 28 pages Platform Option Agreement
12/34/56
EX-10.28
from S-4/A 38 pages Antibody Discovery and Option Agreement
12/34/56
EX-10.32
from S-4 11 pages Korsana Biosciences, Inc. Warrant to Purchase Common Stock
12/34/56
EX-10.27
from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $330,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation
12/34/56
EX-10.26
from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $460,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation
12/34/56
EX-10.25
from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $475,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation
12/34/56
EX-10.24
from S-4 10 pages 1. Positions. as CEO, You Will Report to the Board, and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the CEO Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Will Not Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Expressly Authorized in Writing by the Board. Notwithstanding the Foregoing, You May Engage in Religious, Charitable and Other Community Activities So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company. 2. Compensation
12/34/56